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Editorial
Antiglycolipid antibodies in peripheral neuropathy: fact or fiction?
The past decade has seen the emergence of a large field
of research investigating the concurrence of antiglycolipid
antibodies and peripheral neuropathy (see reviews'-4).
Initial scepticism about the significance of antiganglioside
antibodies is being replaced by a widespread realisation
that these antibodies directly contribute to the pathogen-
esis of neuropathy. Two incompletely resolved issues
which cast doubt on this relation are that raised concen-
trations of antiglycolipid antibodies are very widespread
in normal and disease controls and antiglycolipid anti-
bodies may be either present or absent in clinically indis-
tinguishable neuropathy syndromes. By contrast, some
syndromes such as Miller Fisher syndrome, are very
tightly linked to a specific antiglycolipid antibody in
which conclusive passive transfer studies have been per-
formed. Refining the clinicoserological associations to aid
in diagnosis and to monitor disease progress through
antiglycolipid antibody measurements is becoming more
relevant to patient management. From the research point
of view, considerable efforts are being made to identify
new antibody specificities and to elucidate the precise
mechanisms of action of antiglycolipid antibodies. The
purpose of this editorial is to put a large body of confus-
ing and often conflicting data into a balanced clinical per-
spective with particular emphasis on currently recognised
clinical syndromes and guidance about requesting and
interpreting antiglycolipid antibody assays.
Glycolipid terminology, structure, and function
An early hurdle to cross concerns the complexities of gly-
colipid and ganglioside terminology. Glycosphingolipids
are composed of the long chain aliphatic amine sphingo-
sine (acylated ceramide) attached to one or more sugars
(hexoses). The ceramide is immersed in the membrane
lipid bilayer with the carbohydrate structure exposed
extracellularly. A single hexose linked to ceramide
(monohexosyl-ceramide) is termed a cerebroside, the
most abundant of which in humans is galactocerebroside
(galactosyl-ceramide). Sulphatide is galactocerebroside
sulphated in the carbon-3 position and is a major compo-
nent of peripheral nerve myelin and an autoantigen in
predominantly sensory neuropathies.5-9
Gangliosides are complex glycosphingolipids that, by
definition, must contain at least one sialic acid residue.
Sialic acid is a generic term for N-acylneuraminic acid,
the acyl group generally being acetyl in the human ner-
vous system (as opposed to glycolyl), hence N-acetylneu-
raminic acid, commonly abbreviated to NeuNAc or
NANA. The sialic acid(s) are attached to the internal or
the terminal galactose of an oligosaccharide core com-
posed of up to four sugars with the following sequence:
ceramide-glucose-galactose-N-acetylgalactosamine-galac-
tose. Traditionally, gangliosides are named according to
Svennerholm'0 II with the following formula: G refers to
ganglio; M, D, T, and Q refer to the number of sialic
acid residues (mono, di, tri, and quad respectively);
arabic numerals and lower case letters refer to the
sequence of migration as determined by thin layer chro-
matography. Although dependent on the solvent system
used, bulky gangliosides with a longer oligosaccharide
core and more sialic acid will migrate more slowly than
the smaller gangliosides. For example, for three of the
monosialogangliosides, GM1 (having a four sugar
oligosaccharide core, Cer-Glc-Gal-GalNAc-Gal) migrates
more slowly than GM2 (a three sugar oligosaccharide,
Cer-Glc-Gal-GalNAc), which migrates more slowly than
GM3 (a two sugar oligosaccharide, Cer-Glc-Gal).
Likewise, GDlb runs ahead of GTlb, which runs ahead
of GQlb, as they contain two, three, and four sialic acids
respectively. The figure shows the structure of GDlb.
There are four major gangliosides in the brain (GM1,
GDla, GDlb, GTlb) and many minor gangliosides in
brain and peripheral nerve tissues, which are develop-
mentally regulated and spatially segregated in a wide
range of patterns across different species. Many different
gangliosides can be autoantigens in peripheral neuropa-
thy, some of which have not been identified.'
Paragloboside is a neutral glycolipid (Cer-Glu-Gal-
GlcNAc-Gal), which, when sialylated on the terminal
galactose (sialosylparagloboside, SGP), is a major periph-
eral nerve glycolipid, also known as LMl.*2 Substitution
of the terminal sialic acid for sulphated glucuronic acid
forms sulphated glucuronyl paragloboside (SGPG).'3 14
Both LMI and SGPG are also important peripheral
nerve autoantigens in neuropathy.8 13
All antiglycolipid antibodies associated with neuropa-
thy react with epitopes on the carbohydrate region of the
glycolipid molecules. Because these carbohydrate struc-
tures are often present on several different glycolipids,
glycoproteins, and other carbohydrate rich molecules
such as bacterial lipopolysaccharides, there is consider-
able potential for shared reactivity. For example, (a)
autoantibodies that react with the sulphated glucuronic
acid epitope on SGPG also react with similar epitopes on
many other neural glycoproteins including the myelin
associated glycoprotein (MAG) 13-'5 and the peripheral
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Thin layer chromatogram of 1 yg each of asialo-GM1, GM1, GD3,
GDlb, GTlb, and GQlb, immunostained with two monoclonal IgM
antiganglioside antibodies derivedfrom patients with neuropathy and
showing characteristic patterns of reactivity (see Willison et al 52 for
method). Lane A shows an antibody derivedfrom a patient with a
chronic ataxic neuropathy and IgM paraproteinaemia reactive with
disialosyl epitopes common to GD3, GDlb, GTlb, and GQlb.52 Lane B
shows an antibody derivedfrom an anti-GM1 positive patient reactive
with the Gal(/31-3)GalNAc epitope common to GM1, GDlb, and
asialo-GMI.
nerve compact myelin protein Po06, (b) the
Gal(,B1-3)GalNAc epitope found on GM1 ganglioside is
also present on asialo-GM1 and GDlb (see figure)17-20
and the complete GM1 carbohydrate sequence is present
on Campylobacter jejuni lipopolysaccharide (LPS),2'
Campylobacter enteritis being a common prodromal infec-
tion in patients with Guillain-Barre syndrome,22-25 a pro-
portion of whom have anti-GM1 antibodies.26 27
Glycolipids, including gangliosides, regulate many
diverse physiological processes,28 29 including extensive
modulation of neural cell function.30 They are asymmet-
rically located in the plasma membrane, anchored in the
bilayer by their ceramide tail, exposing their sialylated
oligosaccharide core extracellularly, a site readily accessi-
ble to antibody binding. They are highly enriched in
neural membranes, particularly synaptic regions. They
interact with growth factor receptors, ion channels, and
cell recognition/adhesion molecules and have widespread
effects on signal transduction systems. At the cellular
level, they influence such diverse events as cell survival,
differentiation, synaptogenesis and synaptic transmission,
and neurite outgrowth. In vivo effects include accelerated
restoration of function in injured tissues and neuro-
protection-for example, against glutamate induced
neuronal injury. Considerable research is currently
focused on increasing our understanding of ganglioside
function.
Antiganglioside antibody assays: methodology and
interpretation
Assaying serum samples for antiganglioside and antigly-
colipid antibodies is a process with many pitfalls. There is
no standardised assay method and the literature on this
subject is crowded with different protocols31 that claim
superiority. Two multicentre studies with coded samples
have shown good agreement on clearly positive or nega-
tive cases but discrepancies appear with borderline sam-
ples, which may nevertheless be of important clinical
relevance.3233 Most centres use a combination of enzyme
linked immunosorbent assay (ELISA) with thin layer
chromatography overlay as a confirmatory test. Critical
factors that influence assay results include (a) the choice
of ELISA plates, taking into account manufacture related
batch to batch variations and subsequent storage condi-
tions; (b) the temperature at which the assay is per-
formed; (c) the duration of serum incubation; (d)
washing and blocking buffer composition, particularly the
presence or absence of detergent and the choice of block-
ing protein; (e) sample layout on ELISA plates, with par-
ticular attention to plate stacking artefacts and edge
effects. These factors need to be built into stringent qual-
ity control practice in all laboratories performing assays,
particularly when results influence decisions about diag-
nosis and clinical management.
Assay results are usually reported as titres calculated
by end point analysis (the lowest serum dilution that still
gives a raised optical density reading by ELISA). When
interpreting an assay result, consideration must be given
to the methodology used and the normal range estab-
lished for that laboratory. Because antiganglioside anti-
bodies form part of the normal antibody/autoantibody
repertoire,3435 they are commonplace in normal and dis-
ease control serum samples.3"0 For example, moderately
high IgM and IgG titres (> 1/103 < 1/104) against asialo-
GM1 and sulphatide are typically found in normal serum
samples and are thus not likely to be relevant at this level;
by contrast, an anti-GMI IgM titre of 1/103 is likely to be
relevant as this is above the upper limit of the normal
range (around 1/500) for this antigen in most laborato-
ries.
Antiglycolipid antibody markers for clinical
syndromes
The table lists the main clinical syndromes with a well
defined antiglycolipid antibody specificity. In some situa-
tions, the antiglycolipid antibody assay result will corrob-
Clinical syndromes associated with specific antiglycolipid
autoantibodies
Autoantibody specificity and
Clinical syndrome isotype References
Chronic sensorimnotor Monoclonal IgM antibodies
demyelinating to SGPG, SGLPG, 1-3, 13-16,
neuropathy MAG, and Po 41-46
Chronic axonal sensory IgM antibodies to 5-9
neuropathy sulphatide
Chronic large fibre Monoclonal IgM antibodies 47-53
sensory neuropathy to gangliosides containing
with ataxia NeuNAc(a2-8)NeuNAc
epitopes
Multifocal motor IgM antibodies to GM1 20, 37-40, 58
neuropathy and related Gal(fll-3)
GalNAc bearing glycolipids
Miller Fisher syndrome IgG antibodies to GQlb 54-56, 70, 71
and GTla
Guillain-Barre syndrome IgG, IgM and IgA antibodies 4, 5, 9, 24, 26,
to GMI, GDla, LM1, 37-39, 40,
sulphatide, and other 90-100
glycolipids
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orate a previously suspected diagnosis, such as multifocal
motor neuropathy, or indeed alert the neurophysiologist
to search carefully for conduction block in an apparent
case of lower motor neuron disease in whom multifocal
motor neuropathy was not suspected clinically.
Alternatively, a positive result will further refine an
existing diagnosis, such as paraproteinaemic neuropathy
with anti-MAG specificity or will help to distinguish an
important differential diagnosis, such as Miller Fisher
syndrome, botulism, and brain stem demyelinating
disease.
The first clinical syndrome in which antiglycolipid
antibodies were identified was the IgM paraproteinaemic
neuropathy associated with anti-MAG antibodies.4142 As
well as reacting with MAG and other glycoproteins pre-
sent in peripheral nerve, it was established that the anti-
MAG paraproteins also reacted with the previously
unknown acidic glycolipid, SGPG, and its related homo-
logue, sulphated glucuronyl lactosaminyl paragloboside
(SGLPG).13-15 The clinical syndrome is of a relatively
benign, late onset, chronic sensorimotor demyelinating
neuropathy, often associated with tremor.4344 A patholog-
ical feature of note in nerve biopsies is the presence of
widely spaced myelin.4446 The anti-MAG specificity
accounts for 50% of patients with IgM paraproteinaemic
neuropathy; most of the remainder react with other
glycolipids or gangliosides.1 Some anti-MAG parapro-
teins cross react with sulphatide67 and in addition, sul-
phatide can be a specific and sole antigen in patients with
IgM paraproteinaemic, predominantly sensory, neuro-
pathy.5-7 It is important to recognise, when evaluating
cases of late onset demyelinating neuropathy, that low
level paraproteins may be easily missed by standard elec-
tropheretic techniques and that sensitive screening
methods should be employed.
Another increasingly well defined paraproteinaemic
neuropathy syndrome is a chronic large fibre sensory
neuropathy with prominent ataxia, first described in a
single case report almost a decade ago47 and subsequently
reported by several groups.48-5' In these cases the IgM
paraprotein reacts with gangliosides bearing
NeuNAc(a2-8)NeuNAc linked disialosyl groups, includ-
ing GD3, GDlb, GTlb, and GQlb (figure). There is
some variation in the fine specificity of the antibody
between cases although the clinical pattern is fairly uni-
form. Some of these patients also have cold agglutinin
disease by virtue of the presence of sialylated glycopro-
tein epitopes on human red blood cells. In addition,
some cases have been reported with intermittent opthal-
moplegia,47 thus producing a clinical syndrome reminis-
cent of Miller Fisher syndrome in which antibodies to
disialylated gangliosides are also found.5456
Interest in multifocal motor neuropathy with demyeli-
nating conduction block57 has been intense since it was
recognised that patients with this syndrome may have
antibodies to GM1 gangloiside.58 Early reports indicating a
significant association between anti-GM1 antibodies and
motor neuron disease/amyotrophic lateral sclerosis59 60
were not confirmed by others3738406'-63 although there do
seem to be very rare, unusual cases in which this
occurs.17-19 We screen all patients with predominantly
lower motor neuron syndromes for anti-GMI antibodies.
Many patients with multifocal motor neuropathy and
anti-GM1 antibodies have a fairly stereotyped clinical
picture comprising a chronic asymmetric motor syn-
drome, usually with distal onset in an upper limb, as pre-
viously described.20 64-66 We have not found further
subdivisions on the basis of antiganglioside serology use-
ful, although they have been reported.67 These patients
respond well, albeit temporarily, to intravenous
immunoglobulin68 which is our routine treatment and
can be regularly repeated. Our own experience with
cyclophosphamide has been disappointing (lack of suffi-
cient efficacy to warrant the high risks of toxicity)
although others report success.69
Antiganglioside antibodies are also found in acute
peripheral neuropathies where they appear transiently
and are predominantly of the IgG class. The most clearly
defined association is between anti-GQlb ganglioside
antibodies and Miller Fisher syndrome.54-56 The anti-
GQlb antibodies cross react with GTla in the series of
cases reported by Chiba et a170 and in all our cases to date
(14/14) and with GDlb, GD3, or both in about half of
our cases. Anti-GQlb reactivity seems to specifically
mark the presence of ophthalmoplegia: we have recently
identified a case of acute ataxic, areflexic neuropathy
without opthalmoplegia whose serum samples reacted
only with GDlb and GD3, thereby lending support to
this view. A recent report indicates that anti-GQlb anti-
bodies are also present in Bickerstaffs brain stem
encephalitis, suggesting that there may be a common
aetiological thread to both these conditions.71
In Guillain-Barre syndrome, a wide variety of anti-
ganglioside antibodies have been reported in up to 50%
of cases in different series (table); although no unifying
patterns have yet emerged, they may do so in the future.
Considerable debate surrounds the significance of anti-
GM1 antibodies in Guillain-Barre syndrome. In some
studies, anti-GM1 antibodies mark a particularly severe
form of the illness with prominent motor axonal involve-
ment and poor recovery,262772 although this association is
refuted by others.7374 This issue may be resolvable by fur-
ther subclassification of anti-GM1 antibodies by fine
specificity. In this regard, our recent studies on a panel of
cloned human anti-GM1 antibodies75 have shown con-
siderable heterogeneity in their ability to bind antigen
under different conditions and in their patterns of tissue
reactivity. This may account for the apparent diversity of
clinical expression of anti-GM1 antibody associated
neuropathies and neuronopathies.
The pathogenic relevance of antiglycolipid
antibodies
Despite considerable anomalies and complexities, good
evidence is beginning to emerge from a variety of experi-
mental models to support a direct role for antiganglioside
antibodies in causing neuropathy. Clearly, other factors
including cellular immune mechanisms may play a cen-
tral part in pathogenesis. The subject is complicated by
many factors common to developing an animal model for
disease including qualitative and quantitative variations
in glycolipid antigen composition in nerves from different
species and the lack of well defined human antibodies for
pathogenesis studies. The generation of disease associ-
ated human monoclonal antibodies should help to
resolve this issue.75
Antibodies to SGPG, as found in the "anti-MAG"
IgM paraproteinaemic neuropathy have been shown to
cause demyelination and other pathological changes
including widening of myelin lamellae, when injected
locally into rodent nerve7677 and after systemic passive
transfer to the chicken.78 An intriguing case of anti-MAG
IgM paraproteinaemic neuropathy occurring in conjunc-
tion with hereditary motor and sensory neuropathy has
been described,79 raising the possibility that pre-existing
peripheral nerve abnormalities may predispose to the
development of antinerve antibodies, a fact long recog-
nised in experimental models of nerve injury.80
Experimental studies on anti-GM1 antibodies have
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shown a variety of neuropathic effects including demyeli-
nation and conduction block81-84 although these studies
are clearly incomplete.8586 Antibodies to GMl/GDlb87
and gangliosides bearing disialosyl groups as found in
chronic sensory neuropathies,88 are toxic to cultured
motor neurons and dorsal root ganglion neurons respec-
tively. It has also recently been shown that Miller Fisher
syndrome serum containing anti-GQlb antibody blocks
neurotransmitter release in the mouse hemidiaphragm
preparation, which we postulate accounts for the motor
manifestations of the syndrome.89 Many groups are
actively researching this field, which will undoubtedly
reveal the pathogenic relation between antiglycolipid
antibodies and neuropathy in more detail.
Conclusion
Antiglycolipid antibodies are here to stay as part of the
clinical and experimental investigation of patients with
peripheral neuropathy. The extent to which antiglycol-
ipid antibody assays are requested, however, will depend
on the investigative enthusiasm of individual neurologists
as there are few circumstances in which positive or nega-
tive results play a critical part in patient diagnosis and
management. The field is still in its infancy and a consid-
erable amount of further research is necessary to identify
putative antigens in seronegative cases, or to establish
that such cases are not antibody mediated. This informa-
tion will eventually filter into clinical practice and will
hopefully direct clinicians towards appropriate treatment
and monitoring of antibody mediated neuropathies.
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